Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Pericarditis, Peripheral coldness, SARS-CoV-2 test, Thrombosis, Troponin
Clinical narrative: Positive troponin with level increasing; Myocardial infarction; 3 blood clots; 95% occlusion on LAD, 90% on LAD, -2 and another on diagonal; Pericarditis; Myocarditis; Increased headache/ migraine; Arm pain/pain in feet; Diarrhea; Iced arm; Threw up; Pain radiated up arm a crossed chest into neck and jaw, in base of skull, shoulder blades; Pain radiated up arm a crossed chest into neck and jaw, in base of skull, shoulder blades; Pain radiated up arm a crossed chest into neck and jaw, in base of skull, shoulder blades; Pain radiated up arm a crossed chest into neck and jaw, in base of skull, shoulder blades; Pain radiated up arm a crossed chest into neck and jaw, in base of skull, shoulder blades; Pain radiated up arm a crossed chest into neck and jaw, in base of skull, shoulder blades; Muscle pain; Headache; Nausea; Chills; Dizziness; Difficulty breathing; Pain in feet which increased to blisters; COVID feet; This is a spontaneous report from a contactable other healthcare professional (patient). A 57-year-old non-pregnant female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), dose 1 via an unspecified route of administration, administered in Arm Left on 17Jun2021 17:30 (Batch/Lot Number: EW0172) (at the age of 57 years) as DOSE 1, SINGLE for covid-19 immunisation. Medical history included cardiac disorder, hypothyroidism, migraine, lichen sclerosus, covid-19 from an unknown date. There were no known allergies. There were no other vaccines in four weeks. Concomitant medications included metoprolol taken for an unspecified indication, start and stop date were not reported; levothyroxine taken for an unspecified indication, start and stop date were not reported; clopidogrel bisulfate (PLAVIX) taken for an unspecified indication, start and stop date were not reported; losartan potassium (LOSARTIN) taken for an unspecified indication, start and stop date were not reported. The patient experienced muscle pain, headache, nausea, chills, dizziness, pericarditis, difficulty breathing apx 4-6 hrs after injection (reported as on 17Jun2021 21:30). Increased headache/ migraine, SOB, arm pain and diarrhea apx 8 hrs after injection. On 17Jun2021 21:30, Iced arm, took aspirin, metropolis and migraine meds. Extreme arm pain, upon lying down, pain increased in upper arm and severe trouble breathing. Got up went to bathroom. Severe dizziness, nausea, diarrhea. Threw up. Pain radiated up arm a crossed chest into neck and jaw, in base of skull, shoulder blades, headache increased. Patient went to ER, positive troponin with level increasing, Myocardial infarction -3 blood clots - 95% occlusion on LAD, 90% on LAD, -2 and another on diagonal. 2 stents were placed and patient was sent to ICU. Apx a week later back in ER with migraine, more pericarditis, myocarditis and pain in feet which increased to blisters and COVID feet over 3-4-week period. The events resulted in ER visit, hospitalization, and was reported as life threatening and causing disability or permanent damage. The patient was hospitalized for 3 days. The outcome of events was recovered with lasting effects/sequelae. Therapeutic measures were taken as a result of events (Cardiac intervention/Stents placed). The patient underwent lab tests and procedures which included sars-cov-2 test: negative on 02Aug2021 (Nasal Swab), troponin: positive troponin with level increasing on 17Jun2021.; Sender's Comments: Based on current available information, a possible contributory role of BNT162B2 cannot be completely excluded for the reported events due to temporal relationship.  However, current information is limited and does not allow a full medical assessment. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.